The rational use of dietary supplements, nutraceuticals, and functional foods for the diabetic and prediabetic patient

Nutritional Strategies for the Diabetic and Prediabetic Patient

Volumn , Issue , 2006, Pages 265-296

  Mechanick, Jeffrey I ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 39649111849     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (249)

1. Dalen JE, Is integrative medicine the medicine of the future? A debate between Arnold S. Relman, MD, and Andrew Weil, MD, Arch Int Med, 159:2122-2126, 1999.
2. Goodman NW, Criticizing evidence-based medicine, Thyroid, 10:157-160, 2000.
3. Engel GL, The need for a new medical model: A challenge for biomedicine, Science, 196:129-136, 1977.
4. Steel K, Gertman PM, and Crescenzi C et al., Iatrogenic illness on a general medical service at a university hospital, N Engl J Med, 304:638-642, 1981.
5. Studdert DM, Eisenberg DM, and Miller FH et al., Medican malpractice implications of alternative medicine, JAMA, 280:1610-1615, 1998.
6. Zeisel SH, Regulation of “nutraceuticals,” Science, 285:1853-1855, 1999.
7. Hasler CM, Functional foods: Their role in disease prevention and health promotion, http://www.nutriwatch.org/04Foods/ff.html, Accessed August 29, 2005.
8. Eisenberg DM, Davis RB, and Ettner SL, et al., Trends in alternative medicine use in the United States, 1990-1997, Results of a follow-up national survey, JAMA, 280:1569-1575, 1998.
9. Eisenberg DM, Kessler RC, and Foster C et al., Unconventional medicine in the United States: Prevalence, costs, and patterns of use, N Engl J Med, 328:246-252, 1993.
10. Ryan EA, Pick ME, and Marceau C, Use of alternative medicines in diabetes mellitus, Diabetic Med, 18:242-245, 2001.
11. Ford ES, Vitamin supplement use and diabetes mellitus incidence among adults in the United States. Am J Epidemiol, 153:892-897, 2001.
12. Barringer TA, Kirk JK, and Santaniello AC et al., Effect of a multivitamin and mineral supplement on infection and quality of life, A randomized, double-blind, placebo-controlled trial. Ann Int Med, 138:365-172, 2003.
13. Oubré AY, Carlson TJ, and King SR et al., From plant to patient: An ethnomedical approach to the identification of new drugs for the treatment of NIDDM, Diabetologia, 40:614-617, 1997.
14. Dey L, Attele AS, and Yuan C-S, Alternative therapies for type-2 diabetes, Alt Med Rev, 7:45-58, 2002.
15. Savickiene N, Dagilyte A, and Lukosius A et al., In: Fleming, T, Ed., Importance of biologically active components and plants in the prevention of complications of diabetes mellitus, Medicina (Kaunas), 38:970-975; 2002.
16. PDR for Herbal Medicines, Montvale, NJ: Medical Economics Company, 2000.
17. Grover JK, Yadav S, and Vats V, Medicinal plants of India with anti-diabetic potential, J Ethnopharmacol, 81:81-100, 2002.
18. Bailey CJ and Day C, Traditional plant medicines as treatments for diabetes, Diabetes Care, 12:553, 1989-564.
19. Adusumilli PS, Ben-Porat L, and Pereira M et al., The prevalence and predictors of herbal medicine use in surgical patients, J Am Coll Surg, 198:583-590, 2004.
20. Tomoda M, Shimada K, and Konno C, et al., Partial structure of panaxan A, a hypoglycaemic glycan of Panax ginseng roots, Planta Med, 50:436-438, 1984.
21. Konno C, Sugiyama K, and Kano M, et al., Isolation and hypoglycaemic acitivity of panaxans A, B, C, D, and E, glycans of Panax ginseng roots, Planta Med, 50:434-436, 1984.
22. Konno C, Murakami M, and Oshima Y et al., Isolation and hypoglycemic acitivity of panaxans Q, R, S, T, and U, glycans of Panax ginseng roots, J Ethnopharmacol, 14:69-74, 1985.
23. Yokozawa T, Kobayashi T, and Oura H et al., Studies on the mechanism of the hypoglycemic activity of ginenoside-Rb2 in streptozotocin-diabetic rats, Chem Pharm Bull (Tokyo), 33:869-872, 1985.
24. Oshima Y, Konno C, and Hikino H, Isolation and hypoglycemia acitivity of panaxans I, J, K, and L, glycans of Panax ginseng roots, J Ethnopharmacol, 14:255-259, 1985.
25. Sotaniemi EA, Haapakoski E, and Rautio A, Ginseng therapy in non-insulin-dependent diabetic patients, Diabetes Care, 18:1373-1375, 1995.
26. Vuksan V, Sievenpiper JL, and Koo VY et al., American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type-2 diabetes mellitus, Arch Int Med, 160:1009-1113, 2000.
27. Yuan CS, Wu JA, and Lowell T et al., Gut and brain effects of American ginseng root on brainstem neuronal activities in rats, Am J Chin Med, 26:47-55, 1998.
28. Gillis CN, Panax ginseng pharmacology: A nitric oxide link? Biochem Pharmacol, 54:1-8, 1997.
29. Kimura M, Waki I, and Chujo T et al., Effects of hypoglycemic components in ginseng radix on blood insulin level in alloxan diabetic mice and on insulin release from perfused rat pancreas, J Pharmacolcobiodyn, 4:410-417, 1981.
30. Schulz V, Hansel R, and Tyler VE, Rational phytotherapy, In: Agents that Increase Resistance to Diseases, New York, NY: Springer-Verlag, 269-272, 1998.
31. Welihinda J, Karunanayake EH, and Sheriff MH et al., Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes, J Ethnopharmacol, 17:277-282, 1986.
32. Srivastava Y, Venkatakrishna-Bhatt H, and Verma Y et al., Antidiabetic and adaptogenic properties of Momordica charantia extract, An experimental and clinical evaluation, Phytother Res, 7:285-289, 1993.
33. Akhtar MS, Athar MA, and Yaqub M, Effect of Momordica charantia on blood glucose level of normal and alloxan-diabetic rabbits, Planta Med, 42:205-212, 1981.
34. Bailey CJ and Day C, Traditional plant medicines as treatments for diabetes, Diabetes Care, 12:553, 1989-564.
35. Murase T, Nagasawa A, and Suzuki J et al., Beneficial effects of tea catechins on diet-induced obesity: Stimulation of lipid catabolism in the liver, Int J Obes Relat Metab Disord, 26:1459, 2002-1464.
36. Lapidot T, Walker MD, and Kanner J, Antioxidant and prooxidant effects of phenolics on pancreatic β-cells in vitro, J Agric Food Chem, 50:7220-7225, 2002.
37. Han MK, Epigallocatechin gallate, a constituent of green tea, suppresses styokine-induced pancreatic β-cell damage, Exp Mol Med, 35:136-139, 2003.
38. Chakravarthy BK, Gupta S, and Gambhir SS et al., Pancreatic β-cell regeneration in rats by (-)-epicatechin, Lancet, 2:759-760, 1981.
39. Chakravarthy BK, Gupta S, and Gode KD, Functional β-cell regeneration in the islets of pancreas in alloxan-induced diabetic rats by (-)-epicatechin, Life Sci, 31:2693-2697, 1982.
40. Indian Council of Medical Research (ICMR), Collaborating Centres, New Delhi, Flexible dose open trial of Vijayasar in cases of newly-diagnosed insulin-dependent diabetes mellitus, Indian J Med Res, 108:24-29, 1998.
41. Allen FM, Blueberry leaf extract: Physiological and clinical properties in relation to carbohydrate metabolism, JAMA, 89:1577-1581, 1927.
42. Scharrer A and Ober M, Anthrocyanosides in the treatment of retinopathies (author’s transl.), Klin Monatsbl Augenheikd, 178:386-389 [article in German], 1981.
43. Caselli L, Clinical and electroretinopgraphic study on activity of anthrocyanosides, Arch Med Int, 37:29-35, 1985.
44. Cignarella A, Nastasi M, and Cavalli E et al., Novel lipid-lowering properties of Vaxxinium myrtillus L leaves, a traditional antidiabetic treatment, in several models of rat dyslipidaemia: A comparison with ciprofibrate, Thromb Res, 84:311-322, 1996.
45. Asgary S, Naderi GH, and Sarrafzadegan N et al., Anti-oxidant effect of flavonoids on hemoglobin glycosylation, Pharm Acta Helv, 73:223-226, 1999.
46. Chambers BK and Camire ME, Can cranberry supplementation benefit adults with type-2 diabetes? Diabetes Care, 26:2695-2696, 2003.
47. Kalderon B, Gutman A, and Levy E et al., Characterization of stages in development of obesitydiabetes syndrome in sand rat (Psammomys obesus), Diabetes, 35:717-724, 1986.
48. Yaniv Z, Dafni A, and Friedman J et al., Plants used for the treatment of diabetes in Israel, J Ethnopharmacol, 19:145-151, 1987.
49. Okyar A, Can A, and Akev N et al., Effect of Aloe vera leaves on blood glucose level in type-I and type-II diabetic rat models, Phytother Res, 15:157-161, 2001.
50. Rajasekaran S, Sivagnanam K, and Ravi K et al., Hypoglycemic effect of Aloe vera gel on streptozocininduced diabetes in experimental rats, J Med Food, 7:61-66, 2004.
51. Can A, Akev N, and Ozsoy N et al., Effect of Aloe vera leaf gel and pulp extracts on the liver in type-II diabetic rat models, Biol Pharm Bull, 27:694-698, 2004.
52. Bolkent S, Akev N, and Ozsoy N et al., Effect of Aloe vera (L.) Burm Fil leaf gel and pulp extracts on kidney in type-II diabetic rat models, Indian J Exp Biol, 42:48-52, 2004.
53. Abdullah KM, Abdullah A, and Johnson ML, et al., Effects of Aloe vera on gap junctional intracellular comminuation and proliferation of human diabetic and nondiabetic skin fibroblasts, J Altern Complement Med, 9:711-718, 2003.
54. Ghannam N, Kingston M, and Al-Meshaal IA et al., The antidiabetic activity of aloes: Preliminary clinical and experimental observations, Horm Res, 24:288-294, 1986.
55. Yongchariyudha S, Rungpitarangsi V, Bunyapraphatsara N, and Chokechaijaroenporn O, Antidiabetic activity of Aloe vera L. juice: I, Clinical trial in new cases of diabetes mellitus, Phytomedicine, 3:241, 243, 1996.
56. Bunyapraphatsara N, Yongchaiydha S, and Rungpitarangsi V et al., Antidiabetic activity of Aloe vera L. juice: II, Clinical trial in diabetic mellitus patients in combination with glibenclamide, Phytomedicine, 3:245-248, 1996.
57. Vogler BK and Ernst E. Aloe vera: A systemic review of its clinical effectiveness, Br J Gen Pract, 49:823-828, 1999.
58. Cunnane SC, Ganguli S, and Menard C et al., High alpha-linolenic acid flaxseed (Linum usitatissimum): Some nutritional properties in humans, Br J Nutr, 69:443-453, 1993.
59. Fedorak RN, Cheeseman CI, and Thomson BR et al., Altered glucose carrier expression: Mechanism of intestinal adaptation during streptozotocin-induced diabetic rats, Am J Physiol, 261:G585-591, 1991.
60. Szkudelska K, Nogowski L, and Szkudelski T, Genistein affects lipogenesis and lipolysis in isolated rat adipocytes, J Steroid Biochem Mol Biol, 75:265-271, 2000.
61. Perez C, Canal JR, and Torres MD, Experimental diabetes treated with ficus caria extract: Effect on exidative stress parameters, Acta Diabetol, 40:3-8, 2003.
62. Serraclara A, Hawkins F, and Perez C et al., Hypoglycemic action of an oral fig-leaf decoction in type-I diabetes patients, Diabetes Res Clin Pract, 39:19-22, 1998.
63. Wadood N, Wadood A, and Nisar M, Effect of ficus relegiosa on blood glucose and total lipid levels of normal and alloxan diabetic rabbits, J Ayub Med Coll Abbottabad, 15:40-42, 2003.
64. Daniel RS, Devi KS, and Augusti KT et al., Mechanism of action of antiatherogenic and related effects of Ficus bengalensis linn: Flavonoids in experimental animals, Ind J Exp Biol, 41:296-303, 2003.
65. Geetha BS, Mathew BC, and Augustic KT. Hypoglycemic effects of leucodelphinidin derivative isolated from Ficus bengalensis (linn), Indian J Physiol Pharmacol, 38:220-222, 1994.
66. Frati Munari AC, Vera Lastra O, and Ariza Andraca CR, Evaluation of nopal capsules in diabetes mellitus, Gac Med Mex, 128:431-436, 1992.
67. Frati Munari AC, de Leon C, and Ariza-Andraca R et al., Effect of dehydrated extract of nopal (Opuntia ficus indica mill.) on blood glucose, Arch Invest Med (Mex), 20:211-216, 1989.
68. Frati-Munari AC, Del Valle-Martinez LM, and Ariza-Andraca CR et al., Hypoglycemic action of different doses of nopal (Opuntia streptacantha Lemaire) in patients with type-II diabetes mellitus, Arch Invest Med (Mex), 20:197-201, 1989.
69. Frati-Munari AC, Gordillo BE, and Altamirano P et al., Hypoglycemic effect of Opuntia streptacantha Lemaire in NIDDM, Diabetes Care, 11:63-66, 1988.
70. Frati-Munari AC, Fernandez-Harp JA, and de la Riva H et al., Effects of nopal (Opuntia sp.) on serum lipids, glycemia, and body weight, Arch Invest Med (Mex), 14:117-125, 1983.
71. Ibanez-Camacho R and Roman-Ramos R, Hypoglycemic effect of Opuntia cactus, Arch Invest Med (Mex), 10:223-230, 1979.
72. Soto CP, Perez BL, and Favari LP et al., Prevention of alloxan-induced diabetes mellitus in the rat by silymarin, Comp Biochem Physiol C Pharmacol Toxicol Endocrinol, 119:125-129, 1998.
73. Velussi M, Cernigoi AM, and de Monte A et al., Long-term (12 months) treatment with an antioxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need, and malondialdehyde levels in cirrhotic diabetic patients, J Hepatol, 26:871-879, 1997.
74. Lirussi F, Beccarello A, and Zanette G et al., Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an antioxidant agent, Diabetes Nutr Metab, 15:222-231, 2002.
75. Matsuda T, Ferreri K, and Todorov I et al., Silymarin protects pancreatic β-cells against cytokinemediated toxicity: Implication of c-Jun NH2-terminal kinase and Janus kinase/signal transducer and activator of transcription (STAT) pathways, Endocrinology, 2004. [Epub ahead of print].
76. Saxena A and Vikram NK, Role of selected Indian plants in management of type-2 diabetes, A review, J Alt Compl Med, 10:369-378, 2004.
77. Gupta A, Gupta R, and Lal B, Effect of Trigonella foenum graecum (fenugreek) seeds on glycemic control and insulin resistance in type-2 diabetes mellitus, A double-blind controlled study, J Assoc Physicians India, 49:1057-1061, 2001.
78. Sharma RD, Raghuram TC and Rao NS, Effect of fenugreek seeds on blood glucose and serum lipids in type-1 diabetes, Eur J Clin Nutr, 44:301-306, 1990.
79. Baskaran K, Kizar Ahamath B, and Radha Shanmugasundaram K et al., Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients, J Ethnopharmacol, 30:295-300, 1990.
80. Shanmugasundaram ER, Rajeswari G, and Baskaran K et al., Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus, J Ethnopharmacol, 30:281-294, 1990.
81. Shabib BA, Khan LA, and Rahman R, Hypoglycemic activity of Coccinia indica and Momordica charantia in diabetic rats: Depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-phosphatase and elevation of liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenasse, Biochem J, 292 (Part 1):267-270, 1993.
82. Azad Khan AK, Akhtar S, and Mahtab H, Coccinia indica in the treatment of patients with diabetes mellitus, Bangladesh Med Res Council Bull, 5:60-66, 1979.
83. Khan AK, Akhtar S, and Mahtab H, Treatment of diabetes mellitus with Coccinia indica, Brit Med J, 280:1044, 1980.
84. Kamble SM, Kamlakar PL, and Vaidya S et al., Influence of Coccinia indica on certain enzymes in glycolytic and lipolytic pathway in human diabetes, Ind J Med Sci, 52:143-146, 1998.
85. Platel K and Srinivasan K, Plant foods in the management of diabetes mellitus: Vegetables as potential hypoglycemic agents, Die Nahrung, 41:68-74, 1997.
86. Hossain MZ, Shibib BA, and Rahman R, Hypoglycemic effects of Coccinia indica: Inhibition of key glucogenic enzyme, glucose-6-phosphatase, Ind J Exp Biol, 30:418-420, 1992.
87. Srividya N and Periwal S, Diuretic, hypotensive, and hypoglycemic effects of Phyllanthus amarus. Indian J Exp Biol, 33:861-864, 1995.
88. Hsia SH, Bazargan M, and Davidson MB, Effect of pancreas tonic (an Ayurvedic herbal supplement) in type-2 diabetes mellitus, Metabolism, 53:1166-1173, 2004.
89. Jia W, Gao W and Tang L, Antidiabetic herbal drugs officially approved in China, Phytother Res, 17:1127-1134, 2003.
90. Li WL, Zheng HC, and Bukuru J et al., Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus, J Ethnopharmacol, 92:1-21, 2004.
91. Lui JP, Zhang M, and Wang WY et al., Chinese herbal medicines for type-2 diabetes mellitus, Cochrane Database Syst Rev, CD003642, 2004.
92. Sharma KK, Gupta RK, and Gupta S et al., Antihyperglycemic effect of onion: Effect on fasting blood sugar and induced hyperglycemia in man, Indian J Med Res, 65:422-429, 1977.
93. Jain RC, Vyas CR, and Mahatma OP, Letter: Hypoglycemic action on onion and garlic, Lancet, 2:1491, 1973.
94. Qidwai W, Qureshi R, and Hasan SN et al., Effect of dietary garlic (Allium sativum) on the blood pressure in humans—a pilot study, J Pak Med Assoc 50:204-207, 2000.
95. Sheela CG and Augusti KT, Antidiabetic effects of S-allyl cysteine sulphoxide isolated from garlic Allium sativum Linn, Indian J Exp Biol, 30:523-526, 1992.
96. Campos KE, Diniz YS, and Cataneo AC et al., Hypoglycemia and antioxidant effects of onion, Allium cepa: Dietary onion addition, antioxidant activity and hypoglycaemic effects on diabetic rats, Int J Food Sci Nutr, 54:241-246, 2003.
97. Baluchnejadmojarad T and Roghani M, Endothelium-dependent and-independent effect of aqueous extract of garlic on vascular reactivity on diabetic rats, Fitoterapia, 74:630-637, 2003.
98. Khan BA, Abraham A, and Leelamma S, Hypoglycemic action of Marraya koeingii (curry leaf) and Brassica juncea (mustard): Mechanism of action, Ind J Biochem Biophys, 32:106-108, 1995.
99. Iyer UM and Mani UV, Studies on the effects of curry leave supplementation (Marraya koeingii) on lipid profile, glycated proteins, and amino acids in non-insulin-dependent diabetic patients, Plant Foods Hum Nutr, 40:275-282, 1990.
100. Agrawal P, Rai V, and Singh RB, Randomized placebo-controlled, single blind trial of holy basil leaves in patients with non-insulin-dependent diabetes mellitus, Int J Clin Pharmacol Ther, 34:406-409.), 1996.
101. Oya T, Osawa T, and Kawakishi S, Spice constituents scavenging free radicals and inhibiting pentosidine formation in a model system, Biosci Biotechnol Biochem, 61:263-266, 1997.
102. Akhani SP, Vishwakarma SL, and Goyal RK, Anti-diabetic activity of Zingiber officinale in streptozotocin-induced type-I rats, J Pharm Pharmacol, 56:101-105, 2004.
103. Bordia A, Verma SK, and Srivastava KC, Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigonella foenumgraecum L.) on blood lipids, blood sugar, and platelet aggregation in patients with coronary artery disease, Prostaglandins Leukot Essent Fatty Acids, 56:379-384, 1997.
104. Broadhurst CL, Polansky MM, and Anderson RA, Insulin-like biological activity of culinary and medicinal plant aqueous extracts in vitro, J Agric Food Chem, 48:849-852, 2000.
105. Imparl-Radosevich J, Deas S, and Polansky MM et al., Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: Implications for cinnamon regulation on insulin signaling, Horm Res, 50:177-182, 1998.
106. Khan A, Safdar M, and Khan MMA et al., Cinnamon improves glucose and lipids of people with type-2 diabetes, Diabetes Care, 26:3215-3218, 2003.
107. Anderson RA, Broadhurst CL, and Polansky MM et al. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biologic activity, J Agric Food Chem, 52:65-70, 2004.
108. Grassi D, Necozione S, and Lippi C et al., Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasdilation in hypertensives, Hypertension, 46:398-405, 2005.
109. Grassi D, Lippi C, and Necozione S et al., Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons, Am J clin Nutr, 81:611-614, 2005.
110. Brand-Miller J, Holt SH, and de Jong V et al., Cocoa powder increases postprandial insulinemia in lean young adults, J Nutr, 133:3149-3152, 2003.
111. Keen CL, Holt RR, and Oteiza PI et al., Cocoa antioxidants and cardiovascular health, Am J Clin Nutr, 81(suppl):298-303S, 2005.
112. Zumbe A and Brinkworth RA, Comparative studies of gastrointestinal tolerance and acceptability of milk chocolate containing either sucrose, isomalt or sorbitol in healthy consumers and type II diabetics, Z Ernahrungswiss, 31:40-48, 1992.
113. Gee JM, Cooke D, and Gorick S et al., Effects of conventional sucrose-based, fructose-based and isomalt-based chocolates on postprandial metabolism in non-insulin-dependent diabetics, Eur J Clin Nutr, 45:561-566, 1991.
114. Osakabe N, Yamagishi M, and Natsume M et al., Ingestion of proanthocyanidins derived from cacao inhibits diabetes-induced cataract formation in rats, Exp Biol Med, 229:33-39, 2004.
115. Nguyen NU, Henriet MT, and Dumoulin G et al., Increase in calciuria and oxaluria after a single chocolate bar load, Horm Metab Res, 26:383-386, 1994.
116. Broadhurst CL, Polansky MM, and Anderson RA, Insulin-like biological activity of culinary and medicinal plant aqueous extracts in vitro, J Agric Food Chem, 48:849-852, 2000.
117. Hosoda K, Wang MF, and Liao ML et al., Antihypertensive effect of oolong tea in type-2 diabetics, Diabetes Care, 26:1714-1718, 2003.
118. Waltner-Law ME, Wang XL, and Law BK et al., Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production, J Biol Chem, 277:34933-34940, 2002.
119. Watson JM, Jenkins EJ, and Hamilton P et al., Influence of caffeine on the frequency and perception of hypoglycemia in free-living patients with type-1 diabetes, Diabetes Care, 23:455-459, 2000.
120. van Dam RM and Feskens EJ, Coffee consumption and risk of type-2 diabetes mellitus, Lancet, 360:1477-1478, 2002.
121. Yeomans MR, Caton S, and Hetherington MM, Alcohol and food intake, Curr Op Clin Nutr Metab Care, 6:639-644, 2003.
122. Yeomans MR and Phillips MF, Failure to reduce short-term appetite following alcohol is independent of beliefs about the presence of alcohol, Nutr Neurosci, 5:131-139, 2002.
123. Raben A, Agerholm-Larsen L, and Flint A et al., Meals with similar energy densities but rich in protein, fat, carbohydrate, or alcohol have different effects on energy expenditure and substrate metabolism but not on appetite and energy intake, Am J Clin Nutr, 77:91-100, 2003.
124. Clark JT, Keaton AK, and Sahu A et al., Neuropeptide Y (NPY) levels in alcoholic and food restricted male rats: Implications for site-selective function, Regul Pept, 75-76:335-345, 1998.
125. von meyenberg CW, Langhans W, and Hrupka BJ, Evidence for a role of the 5-HT2C receptor in central lipopolysaccharide-, interleukin-1 beta-, and leptin-induced anorexia, Pharmacol Biochem Behav, 74:1025-1031, 2003.
126. Chester JA and Cunningham CL, GABA(A) receptor modulation of the rewarding and aversive effects of ethanol, Alcohol, 26:131-143, 2002.
127. Widdowson PS and Holman RB, Ethanol-induced increase in endogenous dopamine release may involve endogenous opioids, J Neurochem, 59:157-163, 1992.
128. Hwang MY, Glass RM, and Molter J, Benefits and dangers of alcohol, JAMA, 281:104, 1999.
129. U.S. Department of Agriculture, Dietary Guidelines for Americans 2005, www.healthierus.gov/dietaryguidelines.
130. Davies MJ, Baer DJ, and Judd JT et al., Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women, JAMA, 287:2559-2562, 2002.
131. Greenfield JR, Samaras K, and Hayward CS et al., Beneficial postprandial effect of a small amount of alcohol on diabetes and cardiovascular risk factors: Modification by insulin resistance, J Clin Endocrinol Metab, 90:661-672, 2005.
132. Rimm EB, Chan J, and Stampfer MJ et al., Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men, Br Med J, 310:555-559, 1995.
133. Conigrave KM, Hu BF, and Camargo CA et al., A prospective study of drinking patterns in relation to risk of type-2 diabetes among men, Diabetes, 50:2390-2395, 2001.
134. Kao WH, Puddey IB, and Boland LL et al., Alcohol consumption and the risk of type-2 diabetes mellitus: Athesclerosis risk in communities study, Am J Epidemiol, 154:748-757, 2001.
135. Carlsson S, Hammar N, and Efendic S et al., Alcohol consumption, Type-2 diabetes mellitus and impaired glucose tolerance in middle-aged Swedish men, Diabet Med, 17:776, 2000-781.
136. Wannamethee SG, Camargo CA, Jr, and Manson JE et al., Alcohol drinking patterns and risk of type-2 diabetes mellitus among younger women, Arch Int Med, 163:1329-1336, 2003.
137. Dixon JB, Dixon ME, and O’Brien PE, Alcohol consumption in the severely obese: Relationship with the metabolic syndrome, Obes Res, 10:245-252, 2002.
138. Vernay M, Balkau B, Moreau JG, Sigalas J, Chesnier MC, Ducimetiere P, and The DESIR and Study Group, Alcohol consumption and insulin resistance syndrome parameters: Associations and evolutions in a longitudinal analysis of the French DESIR cohort, Ann Epidemiol, 14:209-214, 2004.
139. Turner BC, Jenkins E, and Kerr D et al., The effect of evening alcohol consumption on next-morning glucose control in type-1 diabetes, Diabetes Care, 24:1888-1893, 2001.
140. Harding AH, Sargeant LA, and Khaw KT et al., Cross-sectional association between total level and type of alcohol consumption and glycosylated haemoglobin levels: The EPIC-Norfolk Study, Eur J Clin Nutr, 56:882-890, 2002.
141. Gin H, Morlat P, and Ragnaud JM et al., Short-term effect of red wine (consumed during meals) on insulin requirement and glucose tolerance in diabetic patients, Diabetes Care, 15:546-548, 1992.
142. Avogara A, Duner E, and Marescotti C et al., Metabolic effects of moderate alcohol intake with meals in insulin-dependent diabetics controlled by artificial endocrine pancreas (AEP) and in normal subjects, Metabolism, 32:463-470, 1983.
143. American and Diabetes Association, American Diabetes Association position statement: Evidencebased nutrition principles and recommendations for the treatment and prevention of diabetes and related complications, J Am Dietetic Assoc, 102:109-118, 2002.
144. Haut MJ and Cowan DH, The effect of ethanol on hemostatic properties of human blood platelets, Am J Med, 56:22-33, 1974.
145. International Life and Sciences Institute, Ethanol stimulates apo A-1 secretion in human hepatocytes: A possible mechanism underlying the cardioprotective effect of ethanol, Nutr Rev, 51:151-152, 1993.
146. Castelli WP, Doyle JT, and Gordon T et al., Alcohol and blood lipids: The cooperative lipoprotein phenotyping study, Lancet, 2:153-155, 1977.
147. Sile SQ, Neese RA, and Hellerstein MK, De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption, Am J Clin Nutr, 70:928-936, 1999.
148. Krauss R and Burke D, Identification of multiple subclasses of plasma low-density lipoproteins in normal humans, J Lipid Res, 23:97-104, 1982.
149. MacDonald I, Ed., Health Issues Related to Alcohol Consumption, Oxford UK: Blackwell Sci 2nd ed., 488, 1999.
150. Thun MJ, Peto FRS, and Lopez AD et al., Alcohol consumption and mortality among middle-aged and elderly U.S. adults, N Engl J Med, 337:1705-1714, 1997.
151. Rimm EB, Klatsky A, and Grobbee D et al., Review of moderate alcohol consumption and reduced risk of coronary heart disease: Is the effect due to beer, wine, or spirits? Br Med J, 312:731-736, 1996.
152. Renaud S and de Lorgeril M, Wine, alcohol, platelets, and the French Paradox for coronary heart disease, Lancet, 339:1523-1526, 1992.
153. German JB and Walzem RL, The health benefits of wine, Annu Rev Nutr, 20:561-593, 2000.
154. Panganga G, Miller N, and Rice-Evans CA, The polyphenolic content of fruit and vegetables and their antioxidant activities: What does a serving constitute? Free Rad Res, 30:153-162, 1999.
155. Maxwell S, Cruickshank A, and Thorpe G, Red wine and antioxidant activity in serum, Lancet, 344:193-194, 1994.
156. Mezzano D, Leighton F, and Martinez C et al., Complementary effects of Mediterranean diet and moderate red wine intake on haemostatic cardiovascular risk factors, Eur J Clin Nutr, 55:444-451, 2001.
157. Duthie GG, Pedersen MW, and Gardner PT et al., The effect of whiskey and wine consumption on total phenol content and antioxidant capacity from healthy volunteers, Eur J Clin Nutr, 52:733-736, 1998.
158. Ceriello A, Bortolotti N, and Motz E et al., Meal-generated oxidative stress in diabetes, The protective effect of red wine, Diabetes Care, 22:2084-2085, 1999.
159. Ceriello A, Bortolotti N, and Motz E et al., Red wine protects diabetic patients from meal-induced oxidative stress and thrombosis activation: A pleasant approach to the prevention of cardiovascular disease in diabetes, Eur J Clin Invest, 31:322-328, 2001.
160. Tessari P, Bruttomesso, and Pianta A et al., Effects of wine intake on postprandial plasma amino acid and protein kinetics in type-1 diabetes, Am J Clin Nutr, 75:856-866, 2002.
161. Jankowski A, Jankowska B, and Niedworok J, The effect of anthocyanin dye from grapes on experimental diabetes, Folia Med Cracov, 41:5-15, 2000.
162. Landrault N, Poucheret P, and Azay J et al., Effect of a polyphenols-enriched Chardonnay white wine in diabetic rats, J Agric Food Chem, 51:311-318, 2003.
163. Aviram M, Rosenblat M, and Billecke S et al., Human serum paraoxonase (PON 1) is inactivated by oxidized low-density lipoprotein and preserved by antioxidants, Free Radic Biol Med, 26:892-904, 1999.
164. Arts IC, Jacobs DR, and Harnack LJ et al., Dietary catechins in relation to coronary heart disease death among postmenopausal women, Epidemiology, 12:668-675, 2001.
165. Rhee SJ, Choi JH, and Park MR, Green tea catechin improves microsomal phospholipase A2 activity and the arachidonic acid cascade system in the kidney of diabetic rats, Asia Pac J Clin Nutr, 11:226-231, 2002.
166. Rizvi SI and Zaid MA, Intracellular reduced glutathione content in normal and type-2 diabetic erythrocytes: Effect of insulin and (-)epicatechin, J Physiol Pharmacol, 52:483-488, 2001.
167. Rizvi SI and Zaid MA, Insulin-like effect of (-)epicatechin on erythrocyte membrane acetylcholinesterase activity in type-2 diabetes mellitus, Clin Exp Pharmacol Physiol, 28:776-778, 2001.
168. Matteucci E, Rizvi SI, and Giampietro O, Erythrocyte sodium/hydrogen exchange inhibition by (-) epicatechin, Cell Biol Int, 25:771-776, 2001.
169. Corder R, Douthwaite JA, and Lees DM et al., Health: Endothelin-1 synthesis reduced by red wine, Nature, 414:863-864, 2001.
170. Chen CK and Pace-Asciak CR, Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta, Gen Pharmacol, 27:363-366, 1996.
171. Wallerath T, Poleo D, and Li H et al., Red wine increases the expression of human endothelial nitric oxide synthase, a mechanism that may contribute to its beneficial cardiovascular effects, J Am Coll Cardiol, 41:471-478, 2003.
172. da Luz PL and Coimbra SR, Wine, alcohol and atherosclerosis: Clinical evidences and mechanisms, Brazilian J Med Biol Res, 37:1275-1295, 2004.
173. Klatsky AL, Armstrong MA, and Friedman GD, Red wine, white wine, liquor, beer, and risk for coronary artery disease hospitalization, Am J Cardiol, 80:416-420, 1997.
174. Hendler SS and Rorvik D, PDR for Nutritional Supplements, Montvale, NJ: Medical Economics Company, 2001.
175. Vincent JB, Recent advances in the nutritional biochemistry of trivalent chromium, Proc Nutr Soc, 63:41-47, 2004.
176. Morris BW, MacNeil S, and Hardisty CA et al., Chromium homeostasis in patients with type-2 (NIDDM) diabetes, J Trace Elem Med Biol, 13:57-61, 1999.
177. Rabinowitz MB, Gonick HC, and Levin SR et al., Effects of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men, Diabetes Care, 6:319-327, 1983.
178. Lee NA and Reasner CA, Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM, Diabetes Care, 17:1449-1452, 1994.
179. Anderson RA, Cheng N, and Bryden NA et al., Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type-2 diabetes, Diabetes, 46:1786-1791, 1997.
180. Bahijiri SM, Mira SA, and Mufti AM et al., The effects of inorganic chromium and brewer’s yeast supplementation on glucose tolerance, serum lipids, and drug dosage in individuals with type-2 diabetes, Saudi Med J, 21:831-837, 2000.
181. Althuis MD, Jordan NE, Ludington EA, and Wittes JT, Glucose and insulin responses to dietary chromium supplements, A meta-analysis, Am J Clin Nutr, 76:148-155, 2002.
182. Uusitupa MI, Mykkanen L, and Siitonen O et al., Chromium supplementation in impaired glucose tolerance of elderly: Effects on blood glucose, plasma insulin, C-peptide, and lipid levels, Br J Nutr, 68:209-216, 1992.
183. Offenbacher EG and Pi-Sunyer FX, Beneficial effects of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects, Diabetes, 29:919-925, 1980.
184. O’Connor JC and Freund GG, Vanadate and rapamycin synergistically enhance insulin-stimulated glucose uptake, Metabolism, 52:666-674, 2003.
185. Badmaev V, Prakash S, and Majeed M, Vanadium: A review of its potential role in the fight against diabetes, J Altern Complement Med, 5:273-291, 1999.
186. Mukherjee B, Patra B, and Mahapatra S et al., Vanadium—an element of atypical biological significance, Toxicol Lett, 150:135-143, 2004.
187. Cohen N, Halberstam M, and Shlimovich P et al., Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus, J Clin Invest, 95:2501-2509, 1995.
188. Halberstam M, Cohen N, and Shlimovich P et al., Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects, Diabetes, 45:659-666, 1996.
189. Aharon Y, Mevorach M, and Shamoon H, Vanadyl sulfate does not enhance insulin action in patients with type-1 diabetes, Diabetes Care, 21:2194-2195, 1998.
190. Goldfine AB, Patti ME, and Zuberi L et al., Metabolic effects of vanadyl sulfate in humans with noninsulin-dependent diabetes mellitus: In vivo and in vitro studies, Metabolism, 49:400-410, 2000.
191. Willsky GR, Goldfine AB, and Kostyniak PJ et al., Effect of vanadium(IV) compounds in the treatment of diabetes: In vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovanadium(IV), J Inorg Biochem, 85:33-42, 2001.
192. Saris NE, Mervaala E, and Karppanen H et al., Magnesium: An update on physiological, clinical, and analytical aspects, Clin Chem Acta, 294:1-26, 2000.
193. Barbagallo M, Dominguez IJ, and Galioto A et al., Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X, Mol Aspects Med, 24:39-52, 2003.
194. Suarez A, Pulido N, and Casla A et al., Impaired tyrosine kinase activity of muscle insulin receptors from hypomagnesaemic rats, Diabetologia, 38:1262-1270, 1995.
195. Kandeel FR, Balon E, and Scott S et al., Magnesium deficiency and glucose metabolism in rat adipocytes, Metabolism, 45:838-843, 1996.
196. Gugliano D, Paolisso G, and Ceriello A, Oxidative stress and diabetic vascular complications, Diabetes Care, 19:257-267, 1996.
197. Ma J, Folsom AR, and Melnick SL et al., Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: The ARIC Study, J Clin Epidemiol, 48:927-940, 1995.
198. Rosolova H, Mayer O, and Reaven GM, Insulin-mediated glucose disposal is decreased in normal subjects with relatively low plasma magnesium concentrations, Metabolism, 49:418-420, 2000.
199. Paolisso G and Barbagallo M, Hypertension, diabetes mellitus, and insulin resistance: The role of intracellular magnesium, Am J Hypertens, 10:346-355, 1997.
200. Kao WH, Folsom AR, and Nieto FJ et al., Serum and dietary magnesium and the risk for type-2 diabetes mellitus: The Atherosclerosis Risk in Communities Study, Arch Int Med, 159:2151-2159, 1999.
201. Song Y, Manson JE, and Buring JE et al., Dietary magnesium intake in relation to plasma insulin levels and risk of type-2 diabetes in women, Diabetes Care, 27:59-65, 2004.
202. Rodriquez-Moran M and Guerrero-Romero F, Oral magnesium supplementation improves insulin sensitivity and metabolic control in type-2 diabetic subjects, A randomized double-blind controlled trial, Diabetes Care, 26:1147-1152; Saris et al., 2000, 2003.
203. Balon TW, Gu JL, and Tokuyama Y et al., Magnesium supplementation reduces development of diabetes in a rat model of spontaneous NIDDM, Am J Physiol, 269:E745-752, 1995.
204. de Lourdes Lima M, Cruz T, and Carreiro Pousada J et al., The effect of magnesium supplementation in increasing doses on the control of type-2 diabetes, Diabetes Care, 21:682-686, 1998.
205. Gullestad L, Jacobsen T, and Dolva LO, Effect of magnesium treatment on glycemic control and metabolic parameters in NIDDM patients, Diabetes Care, 17:460-461, 1994.
206. Eibi NL, Kopp HP, and Nowak HR et al., Hypomagnesemia in type-II diabetes: Effect of a 3-month replacement therapy, Diabetes Care, 18:188-192, 1995.
207. de Valk HW, Verkaaik R, and van Rijn HJ et al., Oral magnesium supplementation in insulin-requiring type-2 diabetic patients, Diabet Med, 15:503-507, 1998.
208. Colditz GA, Manson JE, and Stampfer MJ et al., Diet and risk of clinical diabetes in women, Am J Clin Nutr, 55:1018-1023, 1992.
209. Eibl NL, Kopp HP, and Nowak HR et al., Hypomagnesemia in type-II diabetics: Effect of a 3-month replacement therapy, Diabetes Care, 18:188-192, 1995.
210. Eriksson J and Kohvakka A, Magnesium and ascorbic acid supplementation in diabetes mellitus, Ann Nutr Metab, 39:217-223, 1995.
211. Hagg E, Carlberg BC, and Hillorn VS et al., Magnesium therapy in type-1 diabetes, A double-blind study concerning the effects on kidney function and serum lipid levels, Magnes Res, 12:123-130, 1999.
212. Johnsen SP, Husted SE, and Ravn HB et al., Magnesium supplementation to patients with type-II diabetes, Ugeskr Laeger, 161:945-948, 1999.
213. Lima Mde L, Cruz T, and Pousada JC et al., The effect of magnesium supplementation in increasing doses on the control of type-2 diabetes, Diabetes Care, 21:682-686, 1998.
214. Paolisso G, Scheen A, and Cozzolino D et al., Changes in glucose turnover parameters and improvement of glucose oxidation after 4-week magnesium administration in elderly noninsulin-dependent (type-II) diabetic patients, J Clin Endocrinol Metab, 78:1510-1514, 1994.
215. Roussel AM, Kerkeni A, and Zouari N et al., Antioxidant effects of zinc supplementation in Tunisians with type-2 diabetes mellitus, J Am Coll Nutr, 22:316-321, 2003.
216. Beckman JA, Goldfine AB, and Gordon MB et al., Ascorbate restores endothelium-dependent vasdilation impaired by acute hyperglycemia in humans, Circulation, 103:1618-1623, 2001.
217. Regensteiner JG, Popylisen S, and Bauer TA et al., Oral L-arginine and vitamins E and C improve endothelial function in women with type-2 diabetes, Vasc Med, 8:169-175, 2003.
218. Mullan BA, Young IS, and Fee H et al., Ascorbic acid reduces blood pressure and arterial stiffness in type-2 diabetes, Hypertension, 40:804-809, 2002.
219. Root-Bernstein R, Busik JV, and Henry DN, Are diabetic neuropathy, retinopathy and nephropathy caused by hyperglycemic exclusion of dehydroascorbate uptake by glucose transporters? J Theor Biol, 21:345-359, 2002.
220. Hodgson JM, Watts GF, and Playford DA et al., Coenzyme Q10 improves blood pressure and glycaemic control, Controlled trial in subjects with type-2 diabetes, Eur J Clin Nutr, 56:1137-1142, 2002.
221. Scroggie DA, Albright A, and Harris MD, The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type-2 diabetes mellitus, Arch Int Med, 163:1587-1590, 2003.
222. Physicians’ Desk Reference for Nutritional Supplements, Montvale, NJ: Medical Economics Co, 186-189 2001.
223. Solerte SB, Gazzaruso C, and Schifino N et al., Metabolic effects of orally administered amino acid mixture in elderly subjects with poorly controlled type-2 diabetes mellitus, Am J Cardiol, 93(Suppl 8a):23A-29A, 2004.
224. Aquilani R, Oral amino acid administration in patients with diabetes mellitus: Supplementation or metabolic therapy? Am J Cardiol, 93(Suppl 8a):21A-22A, 2004.
225. Halat KM and Dennehy CE, Botanicals and dietary supplements in diabetic peripheral neuropathy, J Am Board Fam Pract, 16:47-57, 2003.
226. Jamal GA and Carmichael H, The effect of gamma linolenic acid human diabetic peripheral neuropathy, A double-blind placebo-controlled trial, Diabet Med, 7:319-323, 1990.
227. Keen H, Payan J, and Allawi J et al., Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care, 16:8-15, 1993.
228. Purewal TS, Evans PMS, and Havard F et al., Lack of effect of evening primrose oil on autonomic function tests after 12 months of treatment, Diabetologia, 40(Suppl 1):A556, 1997.
229. Ziegler D, Hanefeld M, and Ruhnau KJ et al., Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid, A three-week multicenter randomized controlled trial (ALADIN Study), Diabetologia, 38:1425-1433, 1995.
230. Reljanovic M, Reichel G, and Rett K et al., Treatment of diabetic polyneuropathy with antioxidant thioctic acid (α-lipoic acid), A two-year multi-center randomized double-blind placebo-controlled trial, Alpha Lipoic Acid in Diabetic Neuropathy (ALADIN II), Free Radic Res, 31:171-179, 1999.
231. Ziegler D, Hanefeld M, and Ruhnau KJ et al., Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid, A 7-month multicenter randomized controlled trial (ALADIN III Study), ALADIN III Study Group, Alpha-Lipoic Acid in Diabetic Neuropathy, Diabetes Care, 22:1296-1301, 1999.
232. Ruhnau KJ, Meissner HP, and Finn JR et al., Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy, Diabet Med, 16:1040-1043, 1999.
233. Nagamatsu M, Nickander KK, and Schmelzer JD et al., Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy, Diabetes Care, 18:1160-1167, 1995.
234. Ziegler D, Reljanovic M, and Mehnert H et al., Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany, Current evidence from clinical trials, Exp Clin Endocrinol Diabetes, 107:421-430, 1999.
235. Scheffler NM, Sheitel PL, and Lipton MN, Treatment of painful diabetic neuropathy with capsaicin 0.075%, J Am Podiatr Med Assoc, 81:288-293, 1991.
236. Chad DA, Aronin N, and Lundstrom R et al., Does capsaicin relieve the pain of diabetic neuropathy? Pain, 42:387-388, 1990.
237. The Capsaicin Study Group, Treatment of painful diabetic neuropathy with topical capsaicin— a multicenter, double-blind, vehicle-controlled study, Arch Intern Med, 151:2225-2229, 1991.
238. Tandan R, Lewis GA, and Krusinski PB et al., Topical capsaicin in painful diabetic neuropathy, Controlled study with long-term follow-up, Diabetes Care, 15:8-14, 1992.
239. Low PA, Opfer-Gehrking TL, and Dyck PJ et al., Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful plyneuropathy, Pain, 62:163-168, 1995.
240. Quatraro A, Roca P, and Donzella C et al., Acetyl-L-Carnitine for symptomatic diabetic neuropathy, Diabetologia, 38:123, 1995.
241. Sima AAF, Calvani M, and Mehra M et al., The Acetyl-L-Carnitine and Study Group, Acetyl-LCarnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy, Diabetes Care, 28:89-94, 2005.
242. Abbott CA, Vileikyte L, and Williamson S et al., ALCAR Foot Ulcer Study Group, Effect of treatment with acetyl-L-Carnitine on diabetic foot ulceration in patients with peripheral neuropathy, A 1-year prospective multi-centre study, Diabetologia, 40(Suppl 1):A556, 1997.
243. Jones CL and Gonzalez V, Pyridoxine deficiency: A new factor in diabetic neuropathy, J Am Podiatry Assoc, 68:646-653, 1978.
244. Cohen KL, Gorecki GA, and Silverstein SB et al., Effect of pyridoxine (vitamin B6) on diabetic patients with peripheral neuropathy, J Am Podiatry Assoc, 74:394-397, 1984.
245. Levin ER, Hanscom TA, and Fisher M et al., The influence of pyridoxine in diabetic peripheral neuropathy, Diabetes Care, 4:606-609, 1981.
246. McCann VJ and Davis RE, Pyridoxine and diabetic neuropathy, A double-blind controlled study, Diabetes Care, 6:102-103, 1983.
247. Tutuncu NB, Bayraktar M, and Varli K, Reversal of defective nerve conduction with vitamin E supplementation in type-2 diabetes, A preliminary study, Diabetes Care, 11:915-918, 1998.
248. Sindrup SH, Madsen C, and Bach FW et al., St John’s wort has no effect on pain in polyneuropathy, Pain, 91:361-365, 2001.
249. Yeh GY, Eisenberg DM, and Kaptchuk TJ et al., Systematic review of herbs and dietary supplements for glycemic control in diabetes, Diabetes Care, 26:1277-1294, 2003.